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Abstract
Serotonin has been implicated in the neurobiology of depressive and anxiety disorders, but little is known about its role in the 
modulation of basic emotional processing. The aim of this study was to determine the effect of the selective serotonin reuptake 
inhibitor, escitalopram, on the perception of facial emotional expressions. Twelve healthy male volunteers completed two ex-
perimental sessions each, in a randomized, balanced order, double-blind design. A single oral dose of escitalopram (10 mg) or 
placebo was administered 3 h before the task. Participants were presented to a task composed of six basic emotions (anger, 
disgust, fear, happiness, sadness, and surprise) that were morphed between neutral and each standard emotion in 10% steps. 
Escitalopram facilitated the recognition of sadness and inhibited the recognition of happiness in male, but not female faces. No 
drug effect on subjective measures was detected. These results confirm that serotonin modulates the recognition of emotional 
faces, and suggest that the gender of the face can have a role in this modulation. Further studies including female volunteers 
are needed.
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Selective serotonin reuptake inhibitor (SSRI) agents 
have been widely and successfully used for the pharmaco-
logical treatment of several psychiatric disorders, including 
depressive and anxiety disorders, and the clinical efficacy 
of SSRIs has been attributed to an enhancement of 5-hy-
droxytryptamine (5-HT) neurotransmission (1). Neverthe-
less, little is known about the effect of such drugs on the 
neural mechanisms underlying cognitive and emotional 
processing.
Facial expressions of basic emotions have been used 
for the study of emotional processing, particularly the 
affective information processing, which is an initial step 
related to the search for signals of biological relevance in 
the environment. This processing is likely to be impaired 
in some psychiatric disorders and, in this regard, cognitive 
theories link negative distortions in information processing 
to the onset and/or maintenance of depression and anxiety 
(2). In addition, it has been proposed that antidepressant 
drugs work, at least in part, by reducing a negative bias in 
perception and memory that is believed to initiate and/or 
maintain symptoms of depression and anxiety (3). 
Several studies have shown that changes of 5-HT neu-
rotransmission can modulate the identification of emotional 
faces, particularly fearful faces (reviewed in Ref. 4). Briefly, 
there is evidence showing that the reduction of the availabil-
ity of the precursor of 5-HT synthesis, tryptophan, impairs 
the recognition of facial expressions of fear by healthy 
female, but not male volunteers, without any effect on the 
recognition of other emotional faces. On the other hand, 
the acute dietary supplementation of tryptophan increases 
the identification of happiness and fear by female healthy 
volunteers. Citalopram has been the most used SSRI as a 
challenge for assessing 5-HT functions, probably due to its 
relatively mild side effects and availability for intravenous 
administration. Reported evidence has shown that single 
intravenous administration of 10 mg citalopram facilitates 
the recognition of fearful and happy faces by healthy fe-
male volunteers, and a single oral administration of 20 mg 
citalopram has a similar effect on the recognition of fearful 
faces by healthy volunteers of both genders. In contrast, 
daily oral administration of 20 mg of the drug for 7 days has 
been shown to impair the identification of facial expressions 
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of fear, anger and disgust by healthy female volunteers. 
In the present study, we used escitalopram, the phar-
macologically active S-enantiomer of RS-citalopram, since 
the R-enantiomer has been shown to reduce the effects of 
the S-enantiomer (5), probably due to negative allosteric 
interaction at the level of the 5-HT transporter. As a result, 
escitalopram behaves as a highly potent and selective ligand 
of the 5-HT transporter and, accordingly, clinical studies 
have shown that escitalopram causes few side effects and 
has a relatively fast onset of action (6). 
In view of the reduced number of studies with male 
participants, and data from our laboratory pointing to the 
influence of the phases of the menstrual cycle on emo-
tional processing (7) we initially tested only healthy male 
volunteers. To control for the possible influence of individual 
variability on emotional processing, we used a crossover 
design, assuming that intra-subject comparisons would 
allow the detection of subtle drug effects, which could be 
masked by individual variability. 
Therefore, the objective of this study was to evaluate 
the effect of a single 10-mg dose of the SSRI escitalopram 
on the identification of basic emotional faces by healthy 
male volunteers. In view of previous results showing an 
increase of the recognition of fearful faces induced by a 
single dose of other antidepressants, we hypothesized that 
escitalopram would facilitate the recognition of fear and 
other negative expressions.
Material and Methods 
Participants
The sample was composed of 12 healthy male volun-
teers aged 21 to 27 years (mean = 24.14 years; SD = 2.17), 
evaluated twice in a crossover design (24 experimental 
sessions). 
Psychiatric diagnoses were excluded by the Portuguese 
version of the Structured Clinical Interview for DSM-IV, clini-
cal version (SCID-CV) (8). General medical conditions were 
also excluded by clinical history, physical examination and 
laboratory tests. Misuse of psychoactive substances was 
excluded by medical history and urinary drug screening. 
The volunteers were free of any medication for at least 2 
months before the procedures. Trait anxiety, measured by 
the State-Trait Anxiety Inventory Trait form (STAI-T) (9) was 
low (mean = 29.33; SD = 4.14), varying from 22 to 37.
The study was approved by the Ethics Committee of the 
Faculdade de Medicina de Ribeirão Preto, Universidade 
de São Paulo, and written informed consent was obtained 
from all volunteers. 
Subjective measures
Subjective states were evaluated by the Portuguese 
translation (10) of the Visual Analogue Mood Scale - VAMS 
(11). This scale is composed of 16 items divided into 4 
factors denoted anxiety, sedation, cognitive impairment, 
and discomfort. For each item, the subject was requested 
to mark a point on a 100-mm line between two adjectives 
of opposite meaning, which represented the present feel-
ing. Physical symptoms that can be related to subjective 
anxiety were detected by the Bodily Symptoms Scale - BSS 
(10). The intensity of each symptom is graded from 0 (no 
symptom) to 4 (highest). The total BSS score was the sum 
of the values of all the items for each patient.
Facial expression recognition task
Faces from the Pictures of Facial Affect Series (12) 
portraying six basic emotions (anger, disgust, fear, happi-
ness, sadness, and surprise) had been morphed between 
neutral (0%) and each standard emotion (100%), in 10% 
steps of emotion intensity. For each emotion, 4 pictures, 
2 males and 2 females, were presented for each intensity 
level, comprising 40 stimuli for each emotion. The faces 
were presented on the computer screen for 0.5 s, with 
an interval (blank screen) of 4.5 s between each stimuli. 
Volunteers were asked to choose the response that best 
described the emotion in the picture and to register their 
responses as soon as possible by pressing one of the 
labeled keys on the keyboard.
Procedures
Participants were evaluated twice in sessions separated 
by at least 2 weeks, in a randomized, balanced order, 
double-blind, placebo-controlled, and crossover design. 
They attended the laboratory between 9:00 and 12:00 am 
after a light breakfast. Subjective measures (VAMS and 
BSS) were taken four times: 1) 20 min after arriving to 
the laboratory and just before the capsule intake; 2) 2 h 
after taking the capsule; 3) immediately before starting the 
face recognition task (described above), and 4) just after 
finishing the task.
Oral escitalopram (10 mg) or placebo was given 3 h 
before the task. Placebo and escitalopram capsules were 
prepared by a pharmacist who was unaware of the experi-
mental design. Five volunteers were given placebo in the 
first experimental session and escitalopram in the second; 7 
volunteers were given escitalopram in the first and placebo 
in the second experimental session. Neither the participant 
nor the researcher was aware of the contents of the capsule 
taken during the experimental sessions.
Data analysis
Data were analyzed using the SPSS statistical package 
version 13.0. The area under the curve for the proportion 
of correct answers for each intensity level of the emotion 
(10 steps) for each emotion and for both treatments was 
calculated as an index of individual accuracy in the perfor-
mance in the task and analyzed using repeated measures 
MANOVA (Hotteling’s Trace). An initial analysis of possible 
effects of the repetition of the experiment was carried out 
considering as within-subject factors the experimental 
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session order (first and second) and emotion type (anger, 
disgust, fear, sadness, surprise, and happiness). The drug 
treatment effect was analyzed considering the factors emo-
tion (6), gender of the face (male and female) and treatment 
(escitalopram or placebo). Significant interactions were 
followed by paired t-tests. Subjective measures were also 
analyzed using repeated measures MANOVA, considering 
the factors time (4) and treatment (2). 
Results
Subjective measures
No significant effect of drug treatment was found in the 
VAMS subjective measures (anxiety factor F(1,10) = 0.19; 
P = 0.669; sedation F(1,10) = 0.28; P = 0.606; cognitive 
impairment F(1,10) = 1.16; P = 0.307; discomfort F(1,10) 
= 0.01; P = 0.913) or in the BSS global index (F(1,10) = 
0.15; P = 0.707). Independent of treatment, the volunteers 
reported an increase of subjective anxiety (F(1,10) = 4.54; 
P = 0.025) and of physical symptoms (F(1,10) = 2.43; P = 
0.001) during the experimental session. 
Performance in the facial 
recognition task
No effect of the repetition of the 
experimental session was observed 
(order of the experimental session fac-
tor F(1,10) = 0.33; P = 0.578). 
A single dose of escitalopram (10 
mg) modulated the recognition of facial 
emotional expressions depending on 
the emotion evaluated (emotion and 
treatment interaction, F(5,7) = 9.65; P = 
0.005). Post hoc analyses (paired t-test) 
revealed that escitalopram increased 
the identification of sad faces (t = 5.50; 
d.f. = 11; P < 0.001), and tended to 
increase recognition of angry faces (t = 
1.89; d.f. = 11; P = 0.085), as well as to 
impair identification of surprise (t = 2.11; 
d.f. = 11; P = 0.058) and happiness (t = 
2.04; d.f. = 11; P = 0.067). 
There was also an influence of 
the gender of the face on the effect of 
treatment (emotion, treatment and face) 
gender interaction (F(5,7) = 15.84; P 
= 0.001). As shown in Figure 1, escit-
alopram improved the identification of 
sadness in male faces (t = 8.97; d.f. = 
11; P < 0.001), without any effect on 
female faces (t = 0.62; d.f. = 11; P = 
0.546). The drug also had opposite 
effects on happy faces, impairing the 
recognition in male faces (t = 5.39; d.f. 
= 11; P < 0.001), whereas improving it 
in female faces (t = 2.75; d.f. = 11; P = 0.019). 
Discussion
The main finding of the present study is that escitalo-
pram enhances the identification of sadness and reduces 
the identification of happiness, but the effect occurs mainly 
when the participant views male faces. Two issues arise: 
how does escitalopram enhance perception of sadness 
and reduce happiness perception, and why are males 
more sensitive to this effect when viewing male rather than 
female images? 
The opposite effects of a single administration of escit-
alopram on the recognition of sad and happy faces shown 
by the present results resemble the pattern of response 
observed in depressive disorders. Briefly, depressive pa-
tients have been shown to preferentially attend to sad facial 
expressions over simultaneously presented neutral facial 
expressions and interpret emotionally neutral faces as sad 
faces. This bias seems to be specific to cues signaling sad-
ness, since there is no evidence for preferential allocation 
Figure 1. Accuracy of the identification of emotional faces. Effect of a single dose of 
escitalopram (10 mg) on the accuracy in the identification of sadness (upper panel) 
and happiness (bottom panel) on female and male faces, as a function of face emo-
tion intensity levels (in 10% steps), by 12 male healthy volunteers evaluated twice, in a 
double-blind placebo-controlled crossover design. Data are reported as means ± SD.
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of attention to cues that signal other negative emotions. 
Although less robust, there is also evidence pointing to 
the hypothesis that responsiveness to positive emotional 
cues would be blunted in depressive patients (13). Hence, 
the behavioral effect of acute escitalopram may be consid-
ered to be a “depressive effect”, and this interpretation is 
consistent with the clinical evidence on delayed symptom 
improvement following antidepressant administration and 
the widely accepted view of an impaired 5-HT functioning 
in depression (3). 
However, the interpretation of the effect of a single dose 
of SSRIs on 5-HT function is not straightforward. Some 
microdialysis studies in animals have shown increases in 
cortical extracellular 5-HT following acute SSRI administra-
tion (see, e.g., Ref. 14), but others have shown a greater 
increase of extracellular 5-HT in the raphe nuclei than in 
the neocortex (15). Therefore, it is possible that low acute 
doses of SSRIs preferentially increase 5-HT concentration 
near the cell bodies of serotonergic neurons, reducing their 
firing rate due to the activation of somatodendritic 5-HT1A 
autoreceptors, thus decreasing 5-HT release and lowering 
synaptic 5-HT concentration postsynaptically. According to 
these arguments, the opposite effects of a single administra-
tion of escitalopram on the recognition of sad and happy 
faces shown by the present results suggest a decrease of 
serotonergic transmission. 
In this regard, we have recently shown that a single 
dose of escitalopram given to healthy male volunteers pro-
longed the fear provoked by the simulated public speaking 
test (16). This result resembles the early reported effect 
of a 5-HT2 antagonist in the same test, thus suggest-
ing a decreased functioning of 5-HT neurotransmission. 
In contrast, escitalopram increased plasma cortisol and 
prolactin levels immediately after the speech, suggesting 
an increased 5-HT function (16). This paradox may be 
solved by taking into account animal studies showing that 
the same pharmacological probe could differentially affect 
distinct subpopulations of 5-HT neurons (17), probably 
due to a balance between presynaptic (inhibitory) and 
postsynaptic (excitatory) actions, depending on the kind 
of the environmental stimulus. In this direction, previous 
data have shown that the manipulation of the 5-HT system 
through pharmacological challenges can have different ef-
fects depending on the emotion evaluated. Of significance 
for the present study is the opposite effect of tryptophan 
depletion on sadness and fearfulness observed in healthy 
participants, i.e., decreasing the identification of fearful 
faces, but increasing the recognition of sad faces (Deakin 
B, personal communication).
Previous reports, predominantly regarding female 
participants, found that acute administration of citalopram 
mainly increases the recognition of facial expressions of 
fear (4). However, in this study no effect of escitalopram 
on fear detection was observed. Pharmacodynamic or 
pharmacokinetic properties of escitalopram could be re-
sponsible for these differences. Although escitalopram is 
the S-enantiomer of the racemic compound citalopram, 
many studies indicate that the former is more potent and 
has a more rapid onset of action than the latter (5), and 
SPECT studies have shown that escitalopram has a higher 
serotonin transporter occupancy compared with citalopram 
(18). Thus, these differences may also contribute to the 
discrepancy between the present results with escitalopram 
and the results reported with citalopram. 
Another factor that could have contributed to our results 
is the process of selection of the participants. We were very 
rigorous in the exclusion of any psychiatric disorder through 
semi-structured interviews conducted by skilled clinical 
psychiatrists. These procedures led to a very homogenous 
sample, with low anxiety personality traits. Reported results 
indicate that individuals with high scores of trait-anxiety 
recognize threatening stimuli, including fearful faces, better 
than individuals with low trait-anxiety (19). High levels of 
neuroticism are associated with increased processing of 
negative information in emotional categorization tasks and 
a higher threshold for identifying happiness in facial expres-
sions (20). Thus, personality characteristics can determine 
individual differences in emotional recognition tasks, which 
have been taken into account by the crossover experimental 
design adopted in the first experiment and the inclusion just 
of volunteers with low levels of anxiety.
We also found the impairment of the identification of 
happy faces, another result that is apparently divergent 
from reported findings showing a facilitating effect on the 
recognition of happiness of acute SSRIs (3). Actually, 
when we analyzed the gender of the faces we found that 
escitalopram impaired the recognition of male faces, but 
facilitated the identification of happiness in female faces. 
Therefore, the inconsistency between the present and 
previously reported results may be due to the gender of 
the recognized faces, a factor that has not been evaluated 
in former studies. 
That escitalopram-modulated perception of sadness 
and happiness in faces of the same gender as the viewer 
may reflect a general sensitivity to emotion in faces of one’s 
own gender. Yet, previous studies have not considered the 
interactions between gender of the viewer and gender of 
the faces, which restrains further comparisons. 
Finally, the present lack of effect of escitalopram on 
subjective anxiety suggests that the serotonergic modulation 
of facial expression processing can occur independently 
of changes in the conscious recognition of the feelings 
aroused by emotional faces and independently of changes 
in mood states. This points to a specific effect on early 
preconscious cognitive processing that occurs early in the 
course of treatment and may be related to later clinical 
improvement. Since we did not use standard instruments 
to evaluate depressive state during the procedures, we 
cannot discard the possibility that the facilitation of sadness 
recognition and impairment of happiness recognition would 
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be accompanied by changes in subjective depressive states. 
Further studies must address this issue.
The results obtained in this study need to be appreci-
ated with caution, in view of the small size of the sample, 
possible bias created by the repetition of the experimental 
session and the fact that we studied only male volunteers. 
Further studies including female volunteers are needed to 
understand the interaction between gender of the viewer 
and gender of the face. In spite of these shortcomings, we 
have shown that a single dose of the SSRI escitalopram 
was able to affect the recognition of basic emotions in facial 
expressions by healthy male volunteers, supporting a 5-HT 
modulation of the recognition of emotional faces. In addi-
tion, the present results justify the use of escitalopram as 
a pharmacological tool for exploring the role of 5-HT in the 
normal emotional processing and in the pathophysiology 
of anxiety and depressive disorders. 
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